Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
ImQuest Presentations at International HIV Meeting Highlight Significant Progress in Their Therapeutic and Microbicide Development Programs
January 7th, 2009
ImQuest Life Sciences presented important new results on the continued development of their small molecule pyrimidinedione inhibitors of HIV-1 at the bi-annual HIV-DART meeting held this week in Puerto Rico. The presentations highlighted the development of a second generation therapeutic agent with a highly increased barrier to the selection of drug resistant virus strains in treated patients, as well as formulation and delivery studies with their topical microbicide candidate for human trials, IQP-0528. The pyrimidinediones are highly potent inhibitors of HIV, exhibiting a dual mechanism of action which includes targeting virus entry and reverse transcription, a highly positive safety...
Source: Vaccine Weekly (2009-01-07)
|
